Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, CSL commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
The boathouses along the Schuylkill River date back to the 1800s. Today, they shine at night thanks to a 21st century LED lig…
CSL launches SickonRepeat.com to raise awareness about the symptoms of primary immunodeficiency, a condition that results in …
In honor of Rare Disease Day, we share the voices of patients and caregivers on how others can support them as they manage co…
On a trip supporting the World Federation of Hemophilia’s Humanitarian Aid Program, CSL’s Senior Director of Global Policy an…
Organizers around the world are getting ready to celebrate Rare Disease Day in February. Find out how you can get involved.
Hemophilia B, a bleeding disorder, goes by an alternate name all because of a 5-year-old boy.
We share a report about a 21-year-old student and his journey living with a rare disease.
The CSL Seqirus site in Tullamarine, Melbourne, will be capable of supplying Australia with cell-based flu vaccine and meetin…
Dr Marios Koutsakos announced as the winner of the European Scientific Working Group on Influenza (ESWI) Early Career Scienti…
Americas
Asia Pacific
Middle East
Europe
